Lifetech Scientific
Lifetech Scientific is a Shenzhen-based medical technology company developing, manufacturing and commercializing interventional medical devices, with a focus on cardiovascular and peripheral vascular care.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Lifetech Scientific, known in Chinese as 先健科技, is a medical technology company established in Shenzhen, China, in 1999. The company describes its work as the research and development, production and global development of interventional medical devices, particularly for cardiovascular and peripheral vascular conditions. Its stated mission is to improve lives through innovative interventional medical technology, and its stated vision is to become a globally trusted innovative interventional medical device company. Its business areas include structural heart disease, peripheral vascular disease and cardiac electrophysiology. The company also describes an iron-based bioabsorbable materials platform held through its subsidiary Yuanshin Technology (Shenzhen) Co., Ltd. Its structural-heart portfolio includes devices for congenital heart defects and left atrial appendage closure, while its peripheral vascular business covers aortic, venous and peripheral arterial disease. The company says it is developing a broader electrophysiology offering through international cooperation and collaboration with Jianhu Medical. It reports that its first three core products based on the iron-based platform are at different clinical stages. Named product families and offerings in the company’s milestone history include HeartR, Cera, LAmbre, Ankura, Aegisy, SteerEase, Fustar, SeQure, GoldenFlow, FemFlow, HeartTone, G-iliac and IBS. Regulatory milestones in the company’s history include Chinese NMPA registrations and, for selected products, European CE certifications and US FDA approvals or clinical authorizations. These product and regulatory records reflect a portfolio spanning occluders, stent-graft systems, filters, delivery and access devices, peripheral vascular products, pacing devices and bioabsorbable-device research. Lifetech reports that its sales network reaches nearly 120 countries and regions, supported by more than 1,000 global distributors and seven overseas subsidiaries. The company states that it follows an ‘innovation + internationalization’ strategy and that its principal products have held leading domestic market shares. Its website reports 2,608 patents, including applications, as of June 30, 2026, and says 18 products had entered China’s NMPA special review procedure for innovative medical devices. Lifetech Scientific is listed on the Hong Kong Stock Exchange under stock code 1302.HK. The official website identifies its registered corporate name as Lifetech Scientific (Shenzhen) Co., Ltd. and gives its Shenzhen address as the 14th floor of Lifetech Scientific Building, No. 22 Keji South 12th Road, Nanshan District.
History
Lifetech Scientific was established in Shenzhen in 1999. The company’s official milestones trace its early development through the registration of interventional devices in China. In 2001, its first product, the HeartR patent ductus arteriosus occluder, received NMPA registration approval. Further HeartR devices followed: the atrial septal defect occluder in 2003 and the ventricular septal defect occluder in 2004. That same year, the Ankura aortic stent-graft system was also approved. The Aegisy vena cava filter followed in 2005, and the SteerEase delivery sheath in 2006. The company expanded its international and research footprint in the following years. It was recognized as a national high-tech enterprise in 2008 and established its first overseas subsidiary, Lifetech India. In 2009, the Aegisy filter became its first product to receive European CE certification; the company also records CE certification for Cera occluders and the SteerEase sheath. In 2010, the SeQure lumen retrieval system received US FDA marketing approval, and the company established a postdoctoral research workstation. Other products received European CE certifications that year. A significant corporate milestone came in 2011, when Lifetech listed on the Hong Kong Stock Exchange under stock code 1302.HK. It established a European subsidiary that year, followed by a Netherlands subsidiary in 2012. Further overseas subsidiaries included the United States and Hong Kong in 2015, Greece in 2016 and Germany in 2019. The company’s milestones record a growing range of European CE certifications and Chinese NMPA approvals during this period. Its shares were included in the Hang Seng Index constituent list in 2015 and the Shenzhen-Hong Kong Stock Connect eligible securities list in 2016. The company also developed products that entered China’s special review procedure for innovative medical devices. In 2014, the LAmbre left atrial appendage closure system and IBS bioabsorbable drug-eluting coronary stent system were among the first products accepted into the procedure. Later milestone entries include FemFlow, HeartTone and IrisFit in 2016, and G-iliac in 2017. The company’s 2017 milestones also record NMPA approvals for LAmbre, HeartTone, SeQure, LawMax and Ankura II. In 2018, Lifetech announced a strategic cooperation with global healthcare investment platform Hillhouse Capital Group. In 2019, LAmbre received US FDA authorization to conduct a premarket clinical study, while Aelark received NMPA registration approval. The official milestone extract also lists additional product approvals and developments in 2020, but its supplied text ends partway through that year’s entries. The company’s current profile describes four business areas: structural heart disease, peripheral vascular disease, cardiac electrophysiology and an iron-based bioabsorbable materials platform held through Yuanshin Technology (Shenzhen) Co., Ltd. The company reports a sales network in nearly 120 countries and regions and seven overseas subsidiaries. It states that it continues to pursue an innovation and internationalization strategy, and reports 2,608 patents including applications as of June 30, 2026. It is an active Hong Kong-listed company under the name Lifetech Scientific, stock code 1302.HK.
- 2019
German subsidiary and LAmbre US clinical authorization
[2] - 2018
Strategic cooperation with Hillhouse Capital Group
[2] - 2016
Shenzhen-Hong Kong Stock Connect inclusion and overseas expansion
[2] - 2015
Hang Seng Index inclusion and US subsidiary
[2] - 2014
LAmbre and IBS enter China’s innovative-device special review
[2] - 2011
Listed on the Hong Kong Stock Exchange
[2] - 2010
US FDA marketing approval and research workstation
[2] - 2009
First European CE certification
[2] - 2008
National high-tech enterprise recognition and first overseas subsidiary
[2] - 2001
First product receives NMPA registration approval
[2]
Products and positioning
An innovation-led, internationally oriented interventional medical-device company serving cardiovascular and peripheral vascular care, with a broad portfolio and global distribution network.
HeartR
A family of occluders; the company’s first product was a patent ductus arteriosus occluder.
Ankura
Aortic stent-graft system.
LAmbre
Left atrial appendage closure system.
Aegisy
Vena cava filter system.
IBS
Bioabsorbable drug-eluting coronary stent system.
GoldenFlow
Peripheral stent system.
Controversies
Brand decisions
- Innovation and internationalization strategyOther
Recent events
IBS coronary stent receives EU CE MDR certification[7]
LifeTech Scientific announced that its subsidiary Yuanxin Technology’s IBS bioabsorbable drug-eluting coronary stent system received EU CE MDR certification on October 29, 2026. The announcement described it as the first iron-based coronary stent system to receive sales authorization globally.
Sources7 sources
- 1Lifetech Scientific official homepagelifetechmed.com
- 2Lifetech Scientific milestoneslifetechmed.com
- 3Lifetech Scientific company profilelifetechmed.com
- 4Lifetech Scientific company profilelifetechmed.com
- 5Lifetech Scientific (China)wikidata.org
- 6飞行检查发现10项缺陷被原食药总局通报news.china.com
- 7IBS冠脉支架获得欧盟CE MDR认证cfi.net.cn
Cite this profile: Cite the canonical profile. /brand-wiki/lifetech · Editorial policy · How profiles are compiled